Viking Therapeutics, Inc.

NASDAQ:VKTX

Biotechnology

Healthcare
$26.17 +1.06%

+$0.32 today

Market cap
$3.34B
Beta
0.68
P/E (TTM)
-7.5
EPS (TTM)
-$4.09
52W Low $22.96High $43.15

Volume 2.87M

Average 2.20M

VKTX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Viking Therapeutics, Inc.NASDAQ: VKTX

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization growth accelerates

Q2 FY2026 depreciation & amortization of $157K rose 40.2% year over year, ahead of the +7.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 84.7% from the prior quarter. Over 3 fiscal years it compounded at +14.0% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +40.2% holds above the trailing-twelve-month pace of +7.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$157K+84.7% QoQ
Last fiscal yearDec 2025
$431K+24.6% YoY
LTMJun 2026
$450K+7.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.2%——
1 year+24.6%——
3-year CAGR+14.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
431K USD
Year-over-year change
+24.6%
4-year CAGR
+9.8%

Depreciation & Amortization vs competitors

How VKTX compares with its peers on the latest reported figures

  • VKTX's LTM Jun 2026 depreciation & amortization of $450K is the 3rd highest of the 7 companies compared; the peer median is $326.5K.
  • Its year-over-year change of +7.1% is the 3rd highest of 6, against a peer median of +7.1%.
  • Over three fiscal years its annual growth of +14.0% compares with a peer median of +56.0%.
VKTX Competitors Peer median
Depreciation & Amortization for VKTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$1.52M +7.1%+47.7%0.1%
SEPNSepterna, Inc.LTM Sep 2026$1.25M -21.5%—1.3%
VKTXViking Therapeutics, Inc.LTM Jun 2026$450K +7.1%+14.0%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$343K +39.4%+64.2%—
KLRAKailera Therapeutics, Inc.FY2025$310K ———
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$244K +38.6%+190.2%3.4%
VTVTvTv Therapeutics Inc.LTM Mar 2026$8K -89.5%-44.2%0.0%
Peer median (excluding VKTX) $326.5K+7.1%+56.0%0.7%

Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000431K
Gross Profit0000(431K)
Gross Margin—————
Research & Development44.98M54.23M63.81M101.64M344.96M
Selling, General & Admin10.7M16.12M37.02M49.28M48.39M
Operating Expenses55.68M70.36M100.83M150.92M393.34M
Depreciation & Amortization296K291K292K346K431K
EBITDA(54.68M)(68.52M)(85.52M)(109.52M)(359.15M)
EBITDA Margin—————
Operating Income(55.68M)(70.36M)(100.83M)(150.92M)(393.34M)
Operating Margin—————
Interest Income703K1.59M15.02M40.94M33.7M
Interest Expense18K59K88K94K0
Other Income / Expenses692K1.49M14.93M40.96M33.7M
Income Before Tax(54.99M)(68.87M)(85.9M)(109.96M)(359.64M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(54.99M)(68.87M)(85.9M)(109.96M)(359.64M)
Net Margin—————
EPS (Basic)(0.70)(0.88)(0.91)(1.01)(3.19)
EPS (Diluted)(0.70)(0.88)(0.91)(1.01)(3.19)
Weighted Avg Shares77.2M76.83M94.35M109.04M112.67M
Weighted Avg Shares (Diluted)77.2M76.83M94.35M109.04M112.67M

Viking Therapeutics, Inc.

NASDAQ:VKTX

Intrinsic Alpha fair value

Locked

Current Price

$26.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.